

<b>Studienname</b>	<b>Serena 6</b> <b>A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor</b>
<b>Sponsor/ Studiencode</b>	AstraZeneca D8534C00001
<b>Setting</b>	HR pos. HER2 neg. in der ersten Therapielinie Pre-Screening auf ESR1 Mutation
<b>Primäres Studienziel</b>	PFS
<b>Studiendesign</b>  (Turner N, Future Oncology 2022, doi.org/10.2217/fon-2022-1196)	<p><b>Step one: ESR1m detection phase</b></p> <p>1L standard of care treatment with AI (letrozole or anastrozole) + CDK4/6i (palbociclib or abemaciclib)<sup>a</sup></p> <p>Screening (n = 3000)<sup>b</sup></p> <p>ESR1m surveillance</p> <p>Every 2–3 treatment cycles</p> <p>Tumor imaging per standard of care</p> <p>Centrally tested plasma ctDNA for ESR1 status</p> <p>ESR1m</p> <p>Negative Positive</p> <p>Discontinuation upon disease progression</p> <p><b>Step two: double-blind, randomized treatment phase</b></p> <p>Study treatment<sup>a</sup></p> <p>Key inclusion criteria</p> <ul style="list-style-type: none"> <li>• Histologically confirmed HR+/HER2- ABC</li> <li>• Received ≥6 months of 1L AI (letrozole or anastrozole) plus CDK4/6i (palbociclib or abemaciclib) therapy for ABC with no evidence of disease progression</li> <li>• ECOG PS of 0 or 1</li> <li>• No prior exposure to camizestrant, fulvestrant or an investigational endocrine therapy (in any setting)</li> </ul> <p>Key inclusion criteria</p> <ul style="list-style-type: none"> <li>• ESR1m detected by central testing of ctDNA</li> <li>• Evaluable disease</li> <li>• No evidence of disease progression by investigator assessment</li> <li>• ECOG PS of 0 or 1</li> <li>• Adequate organ and marrow function</li> </ul> <p>Switch to camizestrant (75 mg OD)  Maintain same CDK4/6i  Add placebo for AI</p> <p>Continue AI  Maintain same CDK4/6i  Add placebo for camizestrant</p> <p>Randomization<sup>d</sup> 1:1 n ≈ 300</p>
<b>Einschluss- kriterien (Auswahl)</b>	<ul style="list-style-type: none"> <li>• <b>ESR1m Detektionsphase</b></li> <li>• ER pos. HER2 neg. (IHC Score 0 oder 1+) mBC</li> <li>• In Behandlung und &gt; 6 Monate AI (Letrozol/ Anastrozol) + CDK4/6 (Palbociclib/ Ambemaciclib) in 1 Line für mBC</li> <li>• Eine Line Chemotherapie in mBC <b>erlaubt</b></li> <li>• Stable disease</li> <li>• <b>ESR1m Behandlungsphase</b></li> <li>• ESR1 Mutation</li> <li>• Stable disease</li> </ul>
<b>Ausschluss- kriterien (Auswahl)</b>	<ul style="list-style-type: none"> <li>• <b>ESR1m Detektionsphase/ Screeningphase</b></li> <li>• Behandlung mit Ribociclib in der Screeningphase</li> <li>• Unbehandelte Hirnmetastasen</li> <li>• Maligne Vorgeschichte &lt; 3 Jahre</li> <li>• Fulvestfrant, SERD</li> </ul>
<b>Teilnehmende Zentren</b>	> Essen, KEM